SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2026)
SAB Biotherapeutics (SABS) posted Cash from Financing Activities of $89.9 million for Q1 2026, up 215815.78% on a QoQ basis from -$41685.0 in Q4 2025, and up 51783.26% year-over-year from N/an in Q1 2025.
SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $89.9 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 51783.26% year-over-year to $89.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.4 million (up 27236.78% YoY) and the FY2025 annual result came in at $168.3 million, up 14452.36% from the prior year.
- Cash from Financing Activities was $89.9 million for Q1 2026 at SAB Biotherapeutics, up from -$41685.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $168.7 million in Q3 2025 and bottomed at -$6.3 million in Q1 2022.
- A 5-year average of $19.1 million and a median of -$173985.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 13794.46% — and 2026, when it jumped 51783.26%.
- SAB Biotherapeutics' Cash from Financing Activities stood at $8.4 million in 2022, then soared by 706.4% to $67.6 million in 2023, then sank by 99.68% to $216961.0 in 2024, then plunged by 119.21% to -$41685.0 in 2025, then surged by 215815.78% to $89.9 million in 2026.
- Business Quant data shows SABS's Cash from Financing Activities at $89.9 million in Q1 2026, -$41685.0 in Q4 2025, and $168.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 89.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.92 Mn |
| Mar 31, 2026 | 89.92 Mn |
| Dec 31, 2025 | -41,685.00 |
| Dec 31, 2025 | -41,685.00 |
| Sep 30, 2025 | 168.69 Mn |
| Sep 30, 2025 | 168.69 Mn |
| Jun 30, 2025 | -173,844.00 |
| Jun 30, 2025 | -173,844.00 |
| Mar 31, 2025 | -173,985.00 |
| Mar 31, 2025 | -173,985.00 |
| Dec 31, 2024 | 216,961.00 |
| Dec 31, 2024 | 216,961.00 |
| Sep 30, 2024 | -674,130.00 |
| Sep 30, 2024 | -674,130.00 |
| Jun 30, 2024 | -321,039.00 |
| Jun 30, 2024 | -321,039.00 |
| Mar 31, 2024 | -394,418.00 |
| Mar 31, 2024 | -394,418.00 |
| Dec 31, 2023 | 67.64 Mn |
| Dec 31, 2023 | 67.64 Mn |